Parabilis Medicines (NASDAQ:PBLS) Stock Rated Buy in New Coverage at HC Wainwright

HC Wainwright began coverage on shares of Parabilis Medicines (NASDAQ:PBLS) in a report issued on Thursday morning, Marketbeat Ratings reports. The brokerage issued a buy rating and a $40.00 target price on the stock.

A number of other equities analysts have also weighed in on PBLS. Bank of America assumed coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They set a “buy” rating and a $45.00 target price for the company. Weiss Ratings raised shares of Parabilis Medicines from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, October 16th. Leerink Partners began coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating and a $40.00 price target on the stock. Evercore began coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They set an “outperform” rating on the stock. Finally, Zacks Research raised shares of Parabilis Medicines to a “hold” rating in a report on Tuesday, July 7th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.25.

Parabilis Medicines Price Performance

PBLS stock opened at $24.44 on Thursday. The company has a market cap of $3.02 billion and a P/E ratio of -11.47. Parabilis Medicines has a fifty-two week low of $22.66 and a fifty-two week high of $42.49. The business’s fifty day moving average price is $34.18.

Parabilis Medicines (NASDAQ:PBLS) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($2.32) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The company had revenue of $0.15 million during the quarter. On average, analysts predict that Parabilis Medicines will post -2.60 EPS for the current fiscal year.

Institutional Trading of Parabilis Medicines

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sterling Capital Management LLC bought a new position in Parabilis Medicines in the 3rd quarter valued at $35,000. Persistent Asset Partners Ltd purchased a new position in shares of Parabilis Medicines during the 2nd quarter valued at $113,000. Alyeska Investment Group L.P. purchased a new position in shares of Parabilis Medicines during the 2nd quarter valued at $274,000. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Parabilis Medicines in the second quarter worth $526,000. Finally, WINTON GROUP Ltd bought a new position in shares of Parabilis Medicines in the second quarter worth $955,000.

Key Stories Impacting Parabilis Medicines

Here are the key news stories impacting Parabilis Medicines this week:

• Positive Sentiment: Strong zolucatetide trial results: Updated Phase 1/2 data in desmoid tumors showed a 72.2% objective response rate among patients starting at doses of at least 450 mg, while all 46 evaluable patients achieved disease control and none experienced disease progression. The company also reported a favorable safety and tolerability profile, supporting the drug’s potential for long-term use. Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide
• Positive Sentiment: Clearer regulatory path: Parabilis said it reached alignment with the FDA on the Phase 3 dose regimen, placebo-controlled trial design and progression-free survival as the primary endpoint. The company plans to begin the randomized PEDESTAL Phase 3 study in the first half of 2027, with results expected in 2029. FDA Alignment and Phase 3 Plans
• Positive Sentiment: Analyst remains bullish: HC Wainwright reiterated a “Buy” rating and a $40 price target, well above the recent trading level. Its forecasts call for losses to narrow from an estimated $2.10 per share in fiscal 2026 to $1.55 per share in fiscal 2027. Parabilis Medicines Stock Picked Up by Analysts at HC Wainwright
• Negative Sentiment: Commercial and financial risks remain: Parabilis is still a clinical-stage company with minimal revenue and ongoing losses; its latest reported quarterly EPS significantly missed estimates. The next major value-driving milestone is not expected until Phase 3 begins, with top-line data not anticipated until 2029, leaving substantial clinical, regulatory and funding risk.

About Parabilis Medicines

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.